Scientific conference funding
This article was originally published in The Tan Sheet
FDA will continue to partially support scientific conferences by awarding limited number of grants each fiscal year ranging from $1,000-$25,000 in direct costs per conference, FDA announces in June 6 Federal Register. Agency notes applications will be "reviewed and evaluated for their scientific and technical merit by an ad hoc review panel" that will consider content/subject matter of conference in relation to agency's mission, conference plan, experience of principal investigator/director. FDA requests plans address specific objectives of "Healthy People 2010"...
You may also be interested in...
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”